Cargando…
Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases
Calprotectin is a heterodimeric calcium- and zinc-binding protein mainly derived from the cytoplasm of neutrophils that has direct antimicrobial functions and a role in the regulation of the innate immune response. It can be found in various biological compartments, in particular, the stool, with co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522095/ https://www.ncbi.nlm.nih.gov/pubmed/37440723 http://dx.doi.org/10.14309/ctg.0000000000000617 |
_version_ | 1785110284390629376 |
---|---|
author | Kapel, Nathalie Ouni, Hamza Benahmed, Nacer Adam Barbot-Trystram, Laurence |
author_facet | Kapel, Nathalie Ouni, Hamza Benahmed, Nacer Adam Barbot-Trystram, Laurence |
author_sort | Kapel, Nathalie |
collection | PubMed |
description | Calprotectin is a heterodimeric calcium- and zinc-binding protein mainly derived from the cytoplasm of neutrophils that has direct antimicrobial functions and a role in the regulation of the innate immune response. It can be found in various biological compartments, in particular, the stool, with concentrations related to the level of mucosal inflammation. The measurement of fecal calprotectin has thus been recognized as a useful surrogate marker to distinguish patients with inflammatory bowel disease from those with irritable bowel syndrome. Moreover, it allows the monitoring of intestinal inflammation with a high negative predictive value, making it possible to exclude the diagnosis of inflammatory bowel disease for symptomatic patients. It also shows high sensitivity for the identification of patients requiring additional examinations for diagnosis, such as colonoscopy, and the evaluation of therapeutic responses, providing evidence of relapse or mucosal healing, which can lead to the intensification or reduction of treatment. As calprotectin levels are a measure of mucosal inflammation, high fecal concentrations are also found in other diseases with an inflammatory component, such as infectious enteritis or colorectal cancer. Interpretation of the concentration must therefore always take into account the clinical history and symptoms specific to each patient. |
format | Online Article Text |
id | pubmed-10522095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-105220952023-09-27 Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases Kapel, Nathalie Ouni, Hamza Benahmed, Nacer Adam Barbot-Trystram, Laurence Clin Transl Gastroenterol Clinican's Toolbox Calprotectin is a heterodimeric calcium- and zinc-binding protein mainly derived from the cytoplasm of neutrophils that has direct antimicrobial functions and a role in the regulation of the innate immune response. It can be found in various biological compartments, in particular, the stool, with concentrations related to the level of mucosal inflammation. The measurement of fecal calprotectin has thus been recognized as a useful surrogate marker to distinguish patients with inflammatory bowel disease from those with irritable bowel syndrome. Moreover, it allows the monitoring of intestinal inflammation with a high negative predictive value, making it possible to exclude the diagnosis of inflammatory bowel disease for symptomatic patients. It also shows high sensitivity for the identification of patients requiring additional examinations for diagnosis, such as colonoscopy, and the evaluation of therapeutic responses, providing evidence of relapse or mucosal healing, which can lead to the intensification or reduction of treatment. As calprotectin levels are a measure of mucosal inflammation, high fecal concentrations are also found in other diseases with an inflammatory component, such as infectious enteritis or colorectal cancer. Interpretation of the concentration must therefore always take into account the clinical history and symptoms specific to each patient. Wolters Kluwer 2023-07-14 /pmc/articles/PMC10522095/ /pubmed/37440723 http://dx.doi.org/10.14309/ctg.0000000000000617 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Clinican's Toolbox Kapel, Nathalie Ouni, Hamza Benahmed, Nacer Adam Barbot-Trystram, Laurence Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases |
title | Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases |
title_full | Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases |
title_fullStr | Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases |
title_full_unstemmed | Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases |
title_short | Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases |
title_sort | fecal calprotectin for the diagnosis and management of inflammatory bowel diseases |
topic | Clinican's Toolbox |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522095/ https://www.ncbi.nlm.nih.gov/pubmed/37440723 http://dx.doi.org/10.14309/ctg.0000000000000617 |
work_keys_str_mv | AT kapelnathalie fecalcalprotectinforthediagnosisandmanagementofinflammatoryboweldiseases AT ounihamza fecalcalprotectinforthediagnosisandmanagementofinflammatoryboweldiseases AT benahmednaceradam fecalcalprotectinforthediagnosisandmanagementofinflammatoryboweldiseases AT barbottrystramlaurence fecalcalprotectinforthediagnosisandmanagementofinflammatoryboweldiseases |